Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Paying users zone. Data is hidden behind: .

  • Get 1-month access to Regeneron Pharmaceuticals Inc. for $15.99, or

  • get full access to the entire website for at least 3 months from $49.99.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey
Unlock

This is a one-time payment. There is no automatic renewal.

Regeneron Pharmaceuticals Inc. pages available today for free:

Balance Sheet: Assets
Quarterly Data

Beginner level

The balance sheet provides creditors, investors, and analysts with information on company’s resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company’s assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Regeneron Pharmaceuticals Inc., consolidated balance sheet: assets (quarterly data)

US$ in thousands

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Cash and cash equivalents
Marketable securities
Accounts receivable, trade, net
Accounts receivable, Sanofi
Accounts receivable, other
Inventories
Deferred tax assets
Prepaid expenses and other current assets
Current assets
Marketable securities
Property, plant, and equipment, net
Deferred tax assets
Other noncurrent assets
Noncurrent assets
Total assets

Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07).

Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Regeneron Pharmaceuticals Inc.’s current assets increased from Q4 2019 to Q1 2020 but then slightly decreased from Q1 2020 to Q2 2020 not reaching Q4 2019 level.
Property, plant, and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Regeneron Pharmaceuticals Inc.’s property, plant, and equipment, net increased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Noncurrent assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Regeneron Pharmaceuticals Inc.’s noncurrent assets decreased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Regeneron Pharmaceuticals Inc.’s total assets increased from Q4 2019 to Q1 2020 but then decreased significantly from Q1 2020 to Q2 2020.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Regeneron Pharmaceuticals Inc.’s cash and cash equivalents increased from Q4 2019 to Q1 2020 but then slightly decreased from Q1 2020 to Q2 2020.
Marketable securities Amount of investment in marketable security, classified as current. Regeneron Pharmaceuticals Inc.’s marketable securities increased from Q4 2019 to Q1 2020 but then decreased significantly from Q1 2020 to Q2 2020.
Accounts receivable, trade, net Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Regeneron Pharmaceuticals Inc.’s accounts receivable, trade, net decreased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Inventories Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Regeneron Pharmaceuticals Inc.’s inventories increased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.